These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18831695)

  • 1. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
    Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
    Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.
    Schipani A; Siccardi M; D'Avolio A; Baietto L; Simiele M; Bonora S; Rodríguez Novoa S; Cuenca L; Soriano V; Chierakul N; Saguenwong N; Chuchuttaworn C; Hoskins JM; Dvorak AM; McLeod HL; Davies G; Khoo S; Back DJ; Di Perri G; Owen A
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5242-50. PubMed ID: 20921307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
    Rekić D; Röshammar D; Bergstrand M; Tarning J; Calcagno A; D'Avolio A; Ormaasen V; Vigan M; Barrail-Tran A; Ashton M; Gisslén M; Äbelö A
    AAPS J; 2013 Apr; 15(2):308-15. PubMed ID: 23224752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
    Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV
    Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
    Furtek KJ; Crum NF; Olson PE; Wallace MR
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):394-6. PubMed ID: 16540945
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.
    Goutelle S; Baudry T; Gagnieu MC; Boibieux A; Livrozet JM; Peyramond D; Chidiac C; Tod M; Ferry T;
    Antimicrob Agents Chemother; 2013 Jan; 57(1):517-23. PubMed ID: 23147727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
    Seminari E; Guffanti M; Villani P; Gianotti N; Cusato M; Fusetti G; Galli A; Castagna A; Regazzi M; Lazzarin A
    Eur J Clin Pharmacol; 2005 Aug; 61(7):545-9. PubMed ID: 16041598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.
    D'Avolio A; Carcieri C; Cusato J; Simiele M; Calcagno A; Allegra S; Sciandra M; Trentini L; Di Perri G; Bonora S
    J Antimicrob Chemother; 2014 Nov; 69(11):3061-6. PubMed ID: 24997317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.
    Khanlou H; Farthing C
    J Acquir Immune Defic Syndr; 2005 Aug; 39(4):503. PubMed ID: 16010179
    [No Abstract]   [Full Text] [Related]  

  • 12. Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.
    López Galera RM; Ribera Pascuet E; Esteban Mur JI; Montoro Ronsano JB; Juárez Giménez JC
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1235-6. PubMed ID: 18712519
    [No Abstract]   [Full Text] [Related]  

  • 13. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.
    Guiard-Schmid JB; Poirier JM; Bonnard P; Meynard JL
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):393-4; author reply 394. PubMed ID: 16540944
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients.
    Amadasi S; Odolini S; Foca E; Panzali A; Cerini C; Lonati L; Pezzoli MC; Nasta P; Casari S; Castelli F; Quiros-Roldan E
    Curr HIV Res; 2013 Dec; 11(8):642-6. PubMed ID: 24517189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
    Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
    J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.